11/30
02:17 am
rare
Ultragenyx (RARE): Assessing Valuation as Revenue Growth and Clinical Progress Fuel Renewed Investor Interest [Yahoo! Finance]
Medium
Report
Ultragenyx (RARE): Assessing Valuation as Revenue Growth and Clinical Progress Fuel Renewed Investor Interest [Yahoo! Finance]
11/24
04:30 pm
rare
Ultragenyx to Participate in Investor Conferences in December
Low
Report
Ultragenyx to Participate in Investor Conferences in December
11/24
09:44 am
rare
Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target lowered by analysts at Barclays PLC from $81.00 to $50.00. They now have an "overweight" rating on the stock.
Low
Report
Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target lowered by analysts at Barclays PLC from $81.00 to $50.00. They now have an "overweight" rating on the stock.
11/21
06:11 pm
rare
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Low
Report
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
11/21
04:30 pm
rare
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
11/20
05:23 pm
rare
Ultragenyx And Mereo BioPharma: Considering Their Brittle Bone Disease Phase 3 Trials' Prospect [Seeking Alpha]
Medium
Report
Ultragenyx And Mereo BioPharma: Considering Their Brittle Bone Disease Phase 3 Trials' Prospect [Seeking Alpha]
11/5
02:21 pm
rare
Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target lowered by analysts at TD Cowen from $86.00 to $75.00. They now have a "buy" rating on the stock.
Low
Report
Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target lowered by analysts at TD Cowen from $86.00 to $75.00. They now have a "buy" rating on the stock.
11/5
12:25 pm
rare
Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target lowered by analysts at Truist Financial Corporation from $100.00 to $90.00. They now have a "buy" rating on the stock.
Low
Report
Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target lowered by analysts at Truist Financial Corporation from $100.00 to $90.00. They now have a "buy" rating on the stock.
11/4
04:05 pm
rare
Ultragenyx Reports Third Quarter 2025 Financial Results and Corporate Update
Medium
Report
Ultragenyx Reports Third Quarter 2025 Financial Results and Corporate Update
11/4
04:01 pm
rare
Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $400 Million to OMERS Life Sciences
Low
Report
Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $400 Million to OMERS Life Sciences
10/30
08:00 am
rare
Ultragenyx Announces First Patient Dosed in Aurora Study Evaluating GTX-102 in Additional Angelman Syndrome Genotypes and Age Groups
Medium
Report
Ultragenyx Announces First Patient Dosed in Aurora Study Evaluating GTX-102 in Additional Angelman Syndrome Genotypes and Age Groups
10/28
04:30 pm
rare
Ultragenyx to Host Conference Call for Third Quarter 2025 Financial Results and Corporate Update
Low
Report
Ultragenyx to Host Conference Call for Third Quarter 2025 Financial Results and Corporate Update
10/24
04:30 pm
rare
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
10/20
08:14 am
rare
Ultragenyx Pharmaceutical (NASDAQ:RARE) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $65.00 price target on the stock.
Medium
Report
Ultragenyx Pharmaceutical (NASDAQ:RARE) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $65.00 price target on the stock.
10/8
01:09 am
rare
Bank of America Securities Remains Bullish on Ultragenyx Pharmaceutical (RARE) [Yahoo! Finance]
Medium
Report
Bank of America Securities Remains Bullish on Ultragenyx Pharmaceutical (RARE) [Yahoo! Finance]
10/3
05:08 pm
rare
Assenagon Boosts Ultragenyx Pharmaceutical Inc. (RARE) Stake by 439% Amid Breakthrough Pipeline [Yahoo! Finance]
Low
Report
Assenagon Boosts Ultragenyx Pharmaceutical Inc. (RARE) Stake by 439% Amid Breakthrough Pipeline [Yahoo! Finance]
10/3
04:30 pm
rare
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
10/3
09:03 am
rare
Ultragenyx Pharmaceutical (RARE): Valuation Perspectives Following Regulatory Milestones and Pipeline Progress [Yahoo! Finance]
Low
Report
Ultragenyx Pharmaceutical (RARE): Valuation Perspectives Following Regulatory Milestones and Pipeline Progress [Yahoo! Finance]
9/30
04:05 pm
rare
Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President
Low
Report
Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President
9/30
04:10 am
rare
Cantor Fitzgerald Reiterates a Buy Rating on Ultragenyx Pharmaceutical (RARE) [Yahoo! Finance]
Medium
Report
Cantor Fitzgerald Reiterates a Buy Rating on Ultragenyx Pharmaceutical (RARE) [Yahoo! Finance]
9/19
04:30 pm
rare
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
9/9
08:07 am
rare
Ultragenyx Pharmaceutical (NASDAQ:RARE) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
Low
Report
Ultragenyx Pharmaceutical (NASDAQ:RARE) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
9/8
04:05 pm
rare
Ultragenyx Announces Positive Longer-term Data from Phase 3 Study of DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)
Low
Report
Ultragenyx Announces Positive Longer-term Data from Phase 3 Study of DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)
9/5
10:50 am
rare
Ultragenyx Pharmaceutical (NASDAQ:RARE) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $105.00 price target on the stock.
Low
Report
Ultragenyx Pharmaceutical (NASDAQ:RARE) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $105.00 price target on the stock.